BrainStorm Therapeutics

Startup

At BrainStorm Therapeutics, we are united by a mission to transform the future of brain health. We are building an NSF-funded, NVIDIA award-winning human brain organoid platform that integrates cutting-edge biology with advanced AI to discover and develop disease-modifying therapies for complex brain disorders. Using patient-derived brain organoids engineered with disease-driving mutations, we apply high-throughput screening and AI-driven foundation models to map gene networks, identify validated targets, and advance drug candidates that can reverse disease progression. Our founding team has already demonstrated the power of this approach, advancing a therapeutic candidate for Rett syndrome from organoid screening into a Phase 2 clinical trial. We are now advancing programs in rare genetic neurodevelopmental disorders and conditions involving dopamine neuron dysfunction, including Parkinson’s disease, schizophrenia, and addiction. With its scalability and precision, our platform has the potential to unlock therapies across a broad spectrum of brain disorders.